MIDGE Technology for the Production of a Fourfold Gene-Modified, Allogenic Cell-Based Vaccine for Cancer Therapy
Gene modification of eukaryotic cells by electroporation is a widely used method to express selected genes in a defined cell population for various purposes, like gene correction or production of therapeutics. Here, we describe the generation of a cell-based tumor vaccine via fourfold transient gene modification of a human renal cell carcinoma (RCC) cell line for high expression of CD80, CD154, GM-CSF, and IL-7 by use of MIDGE® vectors. The two co-stimulatory molecules CD80 and CD154 are expressed at the cell surface, whereas the two cytokines GM-CSF and IL-7 are secreted yielding cells with enhanced immunological properties. These fourfold gene-modified cells have been used as a cell-based tumor vaccine for the treatment of RCC.
Key wordsCell-based tumor vaccine MIDGE vector Non-viral vectors Electroporation Transient transfection
We thank Florian Sack for expert review of the manuscript.
- 3.Schmidt M, Volz B, Wittig B (2005) MIDGE Vectors and dSLIM Immunomodulators: DNA-based Molecules for Gene Therapeutic Strategies. In: Knäblein J, Müller RH (eds) Modern Biopharmaceutical. WILEY-VCH Verlag, Weinheim, pp 1–29Google Scholar
- 17.Schmidt M et al (2015) Design and structural requirements of the potent and safe TLR-9agonistic immunomodulator MGN1703. Nucleic Acid Ther (in press)Google Scholar
- 18.Schmoll HJ et al (2014) Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J Cancer Res Clin Oncol, Epub ahead of printGoogle Scholar
- 19.Wittig B et al (2015) MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside. Crit Rev Oncol Hematol 94:31–44Google Scholar
- 20.Grünwald V et al (2014) Final results of patients with metastatic renal cell carcinoma treated with MGN1601 in the ASET study. J Clin Oncol 32(15 suppl), e15590Google Scholar